<qa>  What is the recommended recommended available regimen?Eligible patients are randomized to be treated with the best available therapy recommended for this risk class, standard arm based on phlebotomy including administration of low-dose 100 mgdaily of acetylsalicylic acid ASA, when there are not contraindications OR Pegylated Proline-Interferon alpha-2b AOP2014 every 2 weeks in addition to the recommended available regimen experimental arm, for up to 12 months. The allocation of patients to study arms is 1:1 and stratification at randomization will be performed according to age category 50 years old or 50 years old and time from diagnosis naϊve or non-naϊve. Naive patients are defined as new cases coming to observation, diagnosed for the first time just before study entry and never treated; non-naive patients are old cases diagnosis not older than 3 years before study entry undergoing therapy with phlebotomy andor low doses of ASA. 